ABL Bio, a leader in the field of bispecific antibodies, is gearing up for participation in the upcoming “5th East-West Biopharma Summit: Seoul,” scheduled from March 9 to 11. This summit, co-hosted by BioCentury and BayHelix with McKinsey & Company as an insight partner, aims to foster collaboration and knowledge exchange among industry stakeholders.
Leadership Engagement
Sanghoon Lee, CEO of ABL Bio, will be at the forefront of discussions, participating as a panelist in the “Deal Maker Showcase” on March 10. He intends to share critical insights into successful technology transfer strategies, as well as lessons learned from past negotiations.
Networking Opportunities
The summit will bring together a diverse array of global companies, including major players like Eli Lilly, Roche, Boehringer Ingelheim, MSD, and GSK. ABL Bio plans to leverage this opportunity to engage with these industry leaders, exploring potential partnerships and business development avenues.
Focus on Innovative Technology
A key highlight of ABL Bio’s offerings is its blood-brain barrier (BBB) shuttle platform, known as “Grabody-B.” This innovative technology has already garnered significant interest, evidenced by a noteworthy technology transfer agreement with GSK valued at £2.1401 billion. Furthermore, ABL Bio secured another agreement with Eli Lilly, which included a technology transfer deal totaling USD 2.602 billion and a strategic equity investment agreement of USD 15 million.
Advancements in Immuno-Oncology
In addition to its focus on technology transfer, ABL Bio is committed to advancing clinical trials for its immuno-oncology drugs. Utilizing the 4-1BB-based bispecific antibody platform “Grabody-T,” the company has recently initiated Phase 2 clinical trials for ABL111 (Givastomig), targeting patients undergoing first-line treatment for metastatic gastric cancer.
Expanding Clinical Trials
ABL Bio is not only focused on monotherapy but also aims to expand clinical trials for other pipelines based on the Grabody-T platform to include combination therapies. This strategy underscores the company’s commitment to addressing diverse patient needs through innovative treatment approaches.
A Vision for Success
In reflecting on his participation, Sanghoon Lee expressed his appreciation for the opportunity to share insights at the summit. He emphasized the importance of the experiences gained through the technology transfer process and is optimistic about the potential outcomes of the business meetings scheduled during the event.
Conclusion
As ABL Bio prepares for the East-West Biopharma Summit, its commitment to innovation and collaboration within the biopharma ecosystem stands out. Through strategic partnerships and advanced clinical trials, ABL Bio is poised to make significant strides in the healthcare landscape, ultimately benefiting patients worldwide.
- ABL Bio will participate in the East-West Biopharma Summit from March 9 to 11.
- CEO Sanghoon Lee will share insights on technology transfer and negotiation strategies.
- The company aims to explore business development opportunities with global industry leaders.
- ABL Bio is advancing clinical trials for its bispecific antibody platforms.
- Strategic partnerships with GSK and Eli Lilly highlight ABL Bio’s innovative technology.
Read more → www.asiae.co.kr